Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Rating of “Hold” from Brokerages

Smith & Nephew SNATS, Inc. (NYSE:SNN) has earned an average rating of “Hold” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.9250.

Several research firms have recently weighed in on SNN. Canaccord Genuity Group lowered their price target on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a report on Monday, May 11th. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. Weiss Ratings cut Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Finally, Sanford C. Bernstein set a $31.85 target price on Smith & Nephew SNATS in a research report on Monday, May 11th.

Hedge Funds Weigh In On Smith & Nephew SNATS

Several institutional investors have recently made changes to their positions in the business. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS during the fourth quarter valued at approximately $27,000. Arax Advisory Partners increased its holdings in Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 569 shares during the last quarter. Advisors Asset Management Inc. bought a new position in Smith & Nephew SNATS in the fourth quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new position in Smith & Nephew SNATS in the third quarter worth approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Smith & Nephew SNATS during the 4th quarter worth $43,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Down 1.6%

Shares of SNN stock opened at $30.00 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. Smith & Nephew SNATS has a 12-month low of $28.56 and a 12-month high of $38.79. The firm’s 50 day moving average is $30.21 and its 200 day moving average is $32.46.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.